Merck - Vaccines (2011)

About

- Afluria: Influenza Virus Vaccine (2011-2012 Formula); Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- Comvax: Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine; Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- M-M-R II: Measles, Mumps and Rubella Virus Vaccine Live; Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- Liquid PedvaxHIB: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate).
- Pneumovax 23: Pneumococcal vaccine polyvalent; Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- ProQuad: Combined, attenuated, live virus vaccine containing measles, mumps, rubella, and varicella viruses.
- Recombivax HB: Hepatitis B Vaccine (Recombinant).
- RotaTeq: Rotavirus vaccine, live, oral, pentavalent.
- Tetanus and Diphtheria Toxoids Adsorbed: Manufactured by MassBiologics (University of Massachusetts Medical School) & Distributed by Merck Sharp & Dohme Corp.
- Vaqta: Hepatitis A Vaccine Inactivated - Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- Varivax: Varicella Virus Vaccine Live - Manufactured by CSL Limited & Distributed by Merck Sharp & Dohme Corp.
- Zostavax: Zoster Vaccine Live.

Wyeth - People (2009)

About

- Employees: More than 51,500 people worldwide.
- Employee Networks: Women in Leadership and the Women's Professional Network (site-based women's organizations); Wyeth Latin Network; African Americans Dedicated to Value-Added Networking and Corporate Excellence; Wyeth RAINBOW Alliance (gay, lesbian, bisexual and transgender employee network).
- Diversity Program: Wyeth Corporate Diversity Department; Wyeth Diversity Council.
- Eagles Program: 2 year period program to expedite professional development and enhance leadership capabilities with the view of developing future leaders in Wyeth.
- Executive Leadership Program: 3 day, highly interactive program designed to be the first global, company-wide course that addresses how leaders can be effective in creating environments of teamwork, maintaining quality and developing people.
- Global Leadership Program: 8 day program to develop leadership and strategic thinking skills through a number of activities, including personal assessments, case studies and interactive team challenges.
- Participation in the INROADS Internship program.
- Scholarships to the United Negro College Fund, and the Urban League of Philadelphia (2005-2007).
- Wyeth supports the National Black MBA Association, the National Society of Hispanic MBAs and the National Association of Black Accountants.

GlaxoSmithKline - Vaccines (2009)

About

Vaccines
- ACWY Vax: Meningococcal polysaccharides serogroups A, C, W135 and Y.
- Ambirix: Hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed).
- Arepanrix: AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine.
- Boostrix: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed.
- Cervarix: Human Papillomavirus vaccine (types 16, 18), recombinant, adjuvanted, adsorbed.
- Engerix-B: Hepatitis B Vaccine (Recombinant).
- Fendrix: Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
- Fluarix: Influenza vaccine.
- FluLaval: Influenza vaccine.
- Havrix: Hepatitis A vaccine, inactivated.
- Hepatyrix: Hepatitis A (inactivated, adsorbed) and Typhoid Polysaccharide vaccine.
- Hiberix: Haemophilus B conjugate vaccine (tetanus toxoid conjugate).
- Infanrix: Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed.
- Infanrix IPV: Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed).
- Infanrix IPV + HIB: Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) and Haemophilus influenzae serotype b conjugate vaccine (adsorbed).
- Kinrix: Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine.
- Menitorix: Haemophilus influenza type b Polyribose ribitol phosphate and group C Meningococcal polysaccharide conjugate vaccine.
- Pandemrix: AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine.
- Pediarix: Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined.
- Poliomyelitis: Poliomyelitis monodose vaccine live (oral).
- Priorix: Measles, mumps and rubella vaccine (live attenuated virus).
- Rotarix: Human rotavirus vaccine, live attenuated.
- Twinrix: Combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen).
- Typherix: Typhoid vaccine (purified polysaccharide antigen).
- Varilrix: Varicella in healthy adults and adolescents.

Vaccine Trials

GlaxoSmithKline Argentina Laboratories Company was fined 400,000 pesos by Judge Marcelo Aguinsky following a report issued by the National Administration of Medicine, Food and Technology (ANMAT in Spanish) for irregularities during lab vaccine trials conducted between 2007 and 2008 that allegedly killed 14 babies.
Likewise, two doctors -Héctor Abate, and Miguel Tregnaghi- were fined with 300,000 pesos each for irregularities during the studies.
The charges included experimenting with human beings as well falsifying parental authorizations so babies could participate in vaccine-trials conducted by the laboratory from 2007 to 2008.
Since 2007, 15,000 children under the age of one from Mendoza, San Juan and Santiago del Estero have been included in the research protocol, a statement of what the study is trying to achieve. Babies were recruited from poor families that attended to public hospitals.
A total of seven babies died in Santiago del Estero; five in Mendoza; and two in San Juan.
Pediatrician Ana Marchese, who reported the case through the Argentine Federation of Health Professionals (FESPROSA in Spanish), and was working at the Eva Perón children's public hospital in Santiago del Estero when the studies wee being conducted, said this morning in conversations with Continental AM radio that "GSK Argentina set an protocol at the hospital, and recruited several doctors working there."
"These doctors took advantage of many illiterate parents whom take their children for treatment by pressuring and forcing them into signing these 28-page consent forms and getting them involved in the trials."
"Laboratories can't experiment in Europe or the United States, so they come to do it in third-world countries."
Colombian and Panama were also chosen by GSK as staging grounds for trials of the vaccine against the pneumococcal bacteria.
- By Javier Cardenal Taján, Buenos Aires Herald (January, 2012) -

Wyeth - History

About

- Merged with Pfizer in 2009. Financial advisors: Morgan Stanley and Evercore Partners. Legal advisor: Simpson Thacher & Bartlett LLP.
- Wyeth Pharmaceuticals: 37 manufacturing facilities in 17 countries and markets products in over 60 nations.
- Deutsche Bank Healthcare Conference (2004, 2006, 2007).
- Goldman Sachs Healthcare Conference (2007, 2008, 2009).
- JP Morgan Healthcare Conference (2005, 2006, 2007, 2008, 2009).
- Citigroup Health Care Conference (2005, 2006, 2007, 2008).
- Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference (2005, 2006, 2007).
- Morgan Stanley Pharmaceutical Unplugged Conference (2005, 2006, 2008).
- Net revenue: $22.8 billion in 2008; $22.4 billion in 2007; $20.4 billion in 2006; $18.8 billion in 2005; $15.9 in 2003; $14.6 in 2002.
- Net income: $4,417.8 million in 2008; $4,810.4 million in 2007; $4,280.8 million in 2006; $3,656.3 million in 2005; $3,258.9 million in 2003; $2,962.6 million in 2002.

ViiV Healthcare - Business

About

- Specialist HIV company established by GlaxoSmithKline (85%) and Pfizer (15%).
- Corporate members of the Council on Foreign Relations.

GlaxoSmithKline - Management (2009)

About

- Every second: Distributes more than 35 doses of vaccine.
- Every minute: More than 1,100 prescriptions are written for GSK products.
- Every hour: Spends more than $562,000 to find new medicines.
- Every day: More than 200 million people use a GSK brand toothbrush or toothpaste.
- Every year: Produces 9 billion Tums tablets, 6 billion Panadol tablets and 600 million tubes of toothpaste.
- Corporate member of the Council on Foreign Relations.

Pfizer - Leadership (2009)

About

- Board of Directors: Average Age (65); Council on Foreign Relations (2/12); Former Goldman Sachs Group Inc. (2/12); Former J.P. Morgan Chase & Co. (2/12); Former The Procter & Gamble Company (2/12); Freemason and Trilateral Commission (1/12).
- Pfizer supports the United Nations Global Compact.
- Component of the Dow Jones Industrial Average.
- Funder of RAND Compare.
- Member of The Corporate Council on Africa.
- Corporate member of the Council on Foreign Relations.

Sanofi-Aventis - Governance (2009)

Share Ownership

- January 2009: 11.29% by Total; 8.99% by L'Oréal (30.8% by the Bettencourt Family, 29.6% by Nestlé).
- January 2008: 12.70% by Total; 8.66% by L'Oréal.
- March 2007: 13.12% by Total; 10.52% by L'Oréal.
- Share ownership (January 2006): 12.74% by Total; 10.21% by L'Oréal.
- January 2005: 12.65% by Total; 10.13% by L'Oréal.
- January 2004 (Sanofi-Synthélabo): 24.35% by Total; 19.52% by L'Oréal.
- Sanofi-Synthélabo after the merger: 35.3% by Total; 19.52% by L'Oréal.

Novartis - People (2009)

About

- Approximately 100,000 associates in 140 countries worldwide.
- Revenues: $53 billion in 2008.
- Net sales: $41.5 billion in 2008; $39.8 billion in 2007; $37 billion in 2006.
- Net income: $8.2 billion in 2008; $12.0 billion in 2007; $7.2 billion in 2006.
- Full member of the European Federation of Pharmaceutical Industries and Associations.

Bayer CropScience - Business, Products & People (2009)

The Corbett Report (2018)

About

- AgrEvo = Merger of Hoechst (60%) and Schering (40%) in 1994, integrating the crop protection and pest control business of Roussel Uclaf (more than 10,000 patents worldwide).
- Aventis = Merger of Rhône-Poulenc S.A. and Hoechst AG in 1999.
- Aventis CropScience = Merger of AgrEvo and Rhône-Poulenc Agro.
- Bayer CropScience = Bayer acquires Aventis CropScience in 2002 (biggest acquisition in Bayer history).
- Sales: €6.4 billion in 2008; €5.8 billion in 2007; €5.7 billion in 2006; €5.9 billion in 2005; €5.95 billion in 2004.
- Member of CropLife International.
- Bayer CropScience supports international institutions such as the World Health Organisation, UNICEF, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the U.S. Agency for International Development through its Environmental Science Business Unit.

Baxter - Business & People (2009)

About

- 1980's: Contaminated hemophilia blood products infected HIV and Hepatitis C worldwide.
- 2001: Malfunctioning dialysis machines resulted in several deaths in Spain.
- 2008: Intentional contaminated heparin processed in China from pig's intestines by Scientific Protein Laboratories (Arsenal Capital Partners) resulted in several deaths and serious injuries. Due to procedural errors Changzhou facilities was never subject to an inspection by FDA official, as required by FDA rules. Factory's products also never certified as safe for use in pharmaceutical products by Chinese FDA officials as Changzhou Scientific Protein Laboratories was itself registered as a chemical company and not a drugs manufacturer.
- 2009: Contaminated vaccine material with Avian flu virus sent to a series of European laboratories. Joseph Moshe, dual national (Israeli-American) Mossad biowar expert, attacked and seized by Federal Agents and LAPD in California, after speaking to Dr. True Ott on his national radio show and warning of a plot by Baxter International to spread a Plague from Baxter's Ukrainian lab.
- Net income: $2.2 billion in 2008 ; $1.8 billion in 2007.
- Worldwide sales: $12.3 billion in 2008; $11.3 billion in 2007; $9.8 billion in 2005; $9.5 billion in 2004; $8.9 billion in 2003.

Novartis - Business

About

- Novartis = Merger of Ciba-Geigy Ltd. and Sandoz Laboratories in 1996.
- Ciba-Geigy = Merger of J. R. Geigy Ltd. and Ciba in 1970.
- Revenues: $53 billion in 2008.
- Net sales: $41.5 billion in 2008; $39.8 billion in 2007; $37 billion in 2006.
- Net income: $8.2 billion in 2008; $12.0 billion in 2007; $7.2 billion in 2006.
- Full member of the European Federation of Pharmaceutical Industries and Associations.

GlaxoSmithKline - Wellcome Trust

About

Henry Solomon Wellcome
- Freemason.
- Creates holding company, The Wellcome Foundation Limited (1924).
- Knight Commander of the British Empire and Honorary Fellow of the Royal College of Surgeons of England (1932).
- Collection of around 1.5 million books and objects relating to history and medicine; Artefacts specific to medicine and healing, including large quantities of weapons, bales of fabric, furniture, ancient cooking implements, porcelain, glassware, statues, coins, medals, objets d'art and even torture instruments; Sample of the hair of various historical figures, including George Washington, George III, Napoleon Bonaparte and the Duke of Wellington.
- Funded excavations at Jebel Moya, south of Khartoum, Sudan, hiring 4000 people to excavate (1911-1914).
- Abiding interest in Native American culture, through financial support and political lobbying helped establish a model Christian community amongst the Tsimshean people in British Columbia and establish an alternative site in Alaska.

GlaxoSmithKline - Business & Products

About

- GlaxoSmithKline = Merger of GlaxoWellcome and SmithKline Beecham in 2000 for $75,961 million, 2nd major M&A in the 2000s.
- GlaxoWellcome = Merger of Burroughs Wellcome & Co. and Glaxo Laboratories in 1995.
- SmithKline Beecham = Merger of Beecham and SmithKline in 1989.
- Sales: £24.3 billion in 2008; £22.7 billion in 2007; £23.2 billion in 2006; £21.7 billion in 2005.
- Profit: £7.8 billion in 2008, 2007, 2006; £6.7 billion in 2005.
- Free Cash Flow: £4785 million in 2008; £3857 million in 2007; £4.7 billion in 2005.
- GSK Biologicals S.A. distributed 1.1 billion doses of vaccines to 169 countries, 3 million doses a day, in 2007; and more than 1.2 billion doses of vaccines to 165 countries, more than 3 million doses per day, with £1.1 billion investment in 2005.
- Corporate member of the Council on Foreign Relations.

Pfizer - History

About

- 2000: Merged with Warner-Lambert for $90 billion, 3th major M&A in the last 20 years (-2009).
- 2003: Merged with Pharmacia for $59,515 million, 8th major M&A in the 2000s.
- 2009: Merged with Wyeth.
- Revenue: $50 billion in 2009; $48.3 billion in 2008; $48.4 billion in 2007.
- Adjusted Income: $14.2 billion in 2009; $16.4 billion in 2008; $15.1 billion in 2007.
- Net Income: $8.6 billion in 2009; $8.1 billion in 2008.
- Research & Development: $5.1 billion in 2002; $7.1 billion in 2003; $7.5 billion in 2004; $8.1 billion in 2007; $7.5 billion in 2008; $7.7 billion in 2009.

Sanofi-Aventis - Business

About

- Synthélabo: Created in 1970 and purchased in 1973 by L'Oréal (World's cosmetic leader).
- Sanofi Group: Merger in 1973 of a number of cosmetic, health care, and animal nutrition firms into a corporate subsidiary of the French state-owned Elf Aquitaine oil company (Total).
- Sanofi Bio-industries: Biotechnological center of all Elf Aquitaine's activities.
- Merial = Merger of Merck & Co. Inc. (MSD AgVet) and Sanofi-Aventis (Rhone Mérieux) in 1997.
- Sanofi-Synthélabo = Merger of Sanofi and Synthélabo in 1999.
- Hoechst Marion Roussel = Merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow.
- Aventis = Merger of Rhône-Poulenc S.A. and Hoechst Marion Roussel in 1999.
- Aventis CropScience = Merger of AgrEvo and Rhône-Poulenc Agro in 2000.
- 2004: Sanofi-Synthélabo acquires Aventis by friendly bid of €54.5 billion.
- 2009: Merck sells its 50% of Merial for $4 billion in cash.
- 2010: Equally-owned Joint Venture with Merck by combining Merial (entreprise value fixed at $8 billion) with Intervet/Schering-Plough (entreprise value fixed at $8.5 billion), leading to true-up payment of $250 million to Merck to establish a 50/50 joint venture, and an additional $750 million.
- Full member of the European Federation of Pharmaceutical Industries and Associations.

Merck - Business & Products

About

- Merial = Merger of Merck & Co. Inc. (MSD AgVet) and Sanofi-Aventis (Rhone Mérieux) in 1997. In 2009, Merck sells its 50% to Sanofi-Aventis for $4 billion in cash.
- 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%) for 41.1 billion dollar deal by 56% stock and 44% cash financed with $9.8 billion from existing cash balances and $8.5 billion from committed financing provided by J.P. Morgan.
- 2010: Equally-owned Joint Venture with Sanofi-Aventis by combining Merial (entreprise value fixed at $8 billion) with Intervet/Schering-Plough (entreprise value fixed at $8.5 billion), leading to true-up payment of $250 million to Merck to establish a 50/50 joint venture, and an additional $750 million.
- Supports the United Nations Global Compact.
- Component of the Dow Jones Industrial Average.
- Member of The Corporate Council on Africa.
- Corporate member of the Council on Foreign Relations.

Groupe Grimaud - Vivalis

About

- Virus manufacturing: Production of a large amount of viral vectors and viruses for the manufacture of viral vaccines, such as poxviruses (vaccinia, MVA, fowl pox...), influenza viruses (human, avian and swine strains), adenoviruses (Celo virus...), reoviruses, birnaviruses (Gumboro virus), etc.
- Protein manufacturing: Production of preclinical and clinical lots of recombinant proteins in animals cell lines, including EB66 cells and CHO cells, in cGMP facility at bioreactor scale.
- Development and commercialization of the EBx technology to manufacture viral vaccines (the vaccine market was worth $8.7 billions in 2005 and $10 billions in 2006), and therapeutic proteins and monoclonal antibodies (the protein market was worth $76 billions in 2006).
- Revenue: €7.5 million in 2009; €8.9 million in 2008; €3.2 million in 2007.
- Cash: €42.5 million in 2010; €23.6 million in 2009; €22.7 million in 2008; €25 million in 2007; €1.8 million in 2006.
- R&D Expenses: €9.8 million in 2008; €8.2 million in 2008; €5.5 million in 2007; €4 million in 2006.
- Patents/Licenses: 180/28 in 2009; 116/24 in 2008; 74/22 in 2007; 54/16 in 2006.

Merck - Schering-Plough

About

- Schering-Plough = Merger of Schering Corporation and Plough Inc. in 1971.
- 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%). 41.1 billion dollar deal by 56% stock and 44% cash financed with $9.8 billion from existing cash balances and $8.5 billion from committed financing provided by J.P. Morgan.
- Following the entry of the United States into World War II in 1941, U.S. President Franklin Delano Roosevelt ordered Schering AG's U.S. assets be seized, becoming the Schering Corporation. Placed under a government administratorship until 1952, when it was released and its assets sold to the private sector.
- Business operations: More than 140 countries.
- Net Sales: $20.8 billion in 2008 ; $15.2 billion in 2007 ; $12.5 billion in 2006 ; $10.7 billion in 2005.

Sanofi-Aventis - Sanofi Pasteur

About

- Revenue: €2,861 million in 2008 (+9.6% over 2007).
- Net sales: €2,533 millions in 2006 (+22.7% over 2005).
- Sales Growth in 2008: Pediatric Vaccines (+21.9%).
- Sales of Menactra, meningitis vaccine, in 2007: 415 million euros (+87%). In 2008/2009, production capacities should reach 8 to 10 million doses and 20 million by 2010.
- Vaccines Production Doses: >1.6 billion in 2007 ; >1 billion in 2006.
- More than €1 million invested every day in R&D.
- Nearly €1.5 billion invested in 5 years in production capacity.